BJ9 Stock Overview
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Benitec Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.06 |
| 52 Week High | US$6.46 |
| 52 Week Low | US$1.86 |
| Beta | 1.03 |
| 1 Month Change | 0% |
| 3 Month Change | -2.70% |
| 1 Year Change | -5.31% |
| 3 Year Change | -92.62% |
| 5 Year Change | -99.43% |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| BJ9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -5.3% | -21.1% | -0.3% |
Return vs Industry: BJ9 exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: BJ9 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| BJ9 volatility | |
|---|---|
| BJ9 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BJ9 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BJ9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 18 | Jerel Banks | benitec.com |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Benitec Biopharma Inc. Fundamentals Summary
| BJ9 fundamental statistics | |
|---|---|
| Market cap | €7.60m |
| Earnings (TTM) | -€18.47m |
| Revenue (TTM) | €70.82k |
107.3x
P/S Ratio-0.4x
P/E RatioIs BJ9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BJ9 income statement (TTM) | |
|---|---|
| Revenue | US$75.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$75.00k |
| Other Expenses | US$19.64m |
| Earnings | -US$19.56m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -26,082.67% |
| Debt/Equity Ratio | 0% |
How did BJ9 perform over the long term?
See historical performance and comparison